About Hemanext
Hemanext is a company based in Lexington (United States) founded in 2004 by Martin Cannon.. Hemanext has raised $127.57 million across 10 funding rounds from investors including HHS. The company has 53 employees as of December 31, 2021. Hemanext offers products and services including Hemanext ONE. Hemanext operates in a competitive market with competitors including Brooks Automation, Bridge to Life, Atelerix, Cellbox Solutions and Cold Chain Technologies, among others.
- Headquarter Lexington, United States
- Employees 53 as on 31 Dec, 2021
- Founders Martin Cannon
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hemanext, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$127.57 M (USD)
in 10 rounds
-
Latest Funding Round
$18.9 M (USD), Series B
Jul 22, 2025
- Investors
-
Employee Count
53
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hemanext
Hemanext offers a comprehensive portfolio of products and services, including Hemanext ONE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Processes red blood cells to mitigate storage lesions and improve quality.
Unlock access to complete
Funding Insights of Hemanext
Hemanext has successfully raised a total of $127.57M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $18.9 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series B — $18.9M
-
First Round
First Round
(26 Mar 2009)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series B - Hemanext | Valuation |
investors |
|
| Jan, 2025 | Amount | Series B - Hemanext | Valuation |
investors |
|
| Nov, 2024 | Amount | Series B - Hemanext | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hemanext
Hemanext has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hemanext
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hemanext
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hemanext Comparisons
Competitors of Hemanext
Hemanext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brooks Automation, Bridge to Life, Atelerix, Cellbox Solutions and Cold Chain Technologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vacuum robots for semiconductor wafer handling are developed.
|
|
| domain | founded_year | HQ Location |
Cold storage solutions for organ transplant preservation are provided.
|
|
| domain | founded_year | HQ Location |
Technology for cell storage and transportation is developed.
|
|
| domain | founded_year | HQ Location |
Portable devices for cell storage and transport are provided.
|
|
| domain | founded_year | HQ Location |
Thermal packaging solutions and cold chain monitoring services are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hemanext
Frequently Asked Questions about Hemanext
When was Hemanext founded?
Hemanext was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Where is Hemanext located?
Hemanext is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Who is the current CEO of Hemanext?
Andrew Dunham is the current CEO of Hemanext.
Is Hemanext a funded company?
Hemanext is a funded company, having raised a total of $127.57M across 10 funding rounds to date. The company's 1st funding round was a Series B of $21.71M, raised on Mar 26, 2009.
How many employees does Hemanext have?
As of Dec 31, 2021, the latest employee count at Hemanext is 53.
What does Hemanext do?
Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.
Who are the top competitors of Hemanext?
Hemanext's top competitors include Brooks Automation, Bridge to Life and Atelerix.
What products or services does Hemanext offer?
Hemanext offers Hemanext ONE.
Who are Hemanext's investors?
Hemanext has 1 investor. Key investors include HHS.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.